Kura Oncology, Inc. (KURA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Kura Oncology, Inc. (KURA) closed at USD 9.61 on 2026-10-14, a change of -8.6 % over the past year, with a market capitalization of USD 862.92M.

Kura Oncology, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kura Oncology, Inc. key figures

Previous close

USD 9.61 (2026-10-14)

1-year change

-8.6 %

Market cap

USD 862.92M

Enterprise value

USD 368.35M

P/E ratio (trailing)

-2.88

P/E ratio (forward)

-4.13

EPS (trailing)

-3.37

EPS (forward)

-2.35

PEG ratio

n/a

Price to book

17.83

Revenue growth

36.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.92

Employees

260

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kura Oncology, Inc. and compare it with other stocks.